Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Thermo Fisher, UCSF to Open Cell Therapy cGMP Mfg. Center | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Thermo Fisher, UCSF to Open Cell Therapy cGMP Mfg. Center

Thermo Fisher will build and operate a 44,000-sq.-ft. cell therapy development, manufacturing and collaboration center on UCSF's Mission Bay campus.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Thermo Fisher Scientific Inc. and the University of California, San Francisco (UCSF) formed a strategic alliance to accelerate the development and manufacture of cell-based therapies.

Thermo Fisher will build and operate a 44,000-square-foot, state-of-the-art cell therapy development, manufacturing and collaboration center in leased space on UCSF’s Mission Bay campus, which includes biomedical research facilities and hospitals. The site will offer clinical and commercial cGMP cell therapy manufacturing services, along with associated technology development support, to UCSF and other partners.
 
The facility is expected to open in 2022 and will also serve as a central location where customers and UCSF researchers will have access to Thermo Fisher’s portfolio of Cell Therapy Systems (CTS) reagents, consumables, and fit-for-purpose instrumentation and software. The CTS product portfolio is designed to work seamlessly from research to clinical manufacturing to address cell therapy production workflow challenges.
 
“We are bringing together UCSF’s leadership in the newest forms of cellular immunotherapy and Thermo Fisher’s extensive capabilities in cell therapy instrumentation, manufacturing and distribution,” said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. “This powerful combination will provide customers – from emerging biotechs to large pharma companies – with integrated, end-to-end solutions to reduce costs and accelerate adoption of cell therapies, ultimately improving patient access to these transformative treatments.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics